Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Global impact and cost-effectiveness of one-dose versus two-dose human papillomavirus vaccination schedules: a comparative modelling analysis
Kiesha Prem, Yoon Hong Choi, Élodie Bénard, et al.
BMC Medicine (2023) Vol. 21, Iss. 1
Open Access | Times Cited: 31

Showing 1-25 of 31 citing articles:

Vaccine efficacy against persistent human papillomavirus (HPV) 16/18 infection at 10 years after one, two, and three doses of quadrivalent HPV vaccine in girls in India: a multicentre, prospective, cohort study
Partha Basu, Sylla G. Malvi, Smita Joshi, et al.
The Lancet Oncology (2021) Vol. 22, Iss. 11, pp. 1518-1529
Open Access | Times Cited: 176
Efficacy of Single-Dose Human Papillomavirus Vaccination among Young African Women
Ruanne V. Barnabas, Elizabeth R. Brown, Maricianah Onono, et al.
NEJM Evidence (2022) Vol. 1, Iss. 5
Open Access | Times Cited: 131
Updates on HPV Vaccination
Ojone Illah, Adeola Olaitan
Diagnostics (2023) Vol. 13, Iss. 2, pp. 243-243
Open Access | Times Cited: 59
Gender neutral HPV vaccination programs: Reconsidering policies to expand cancer prevention globally
J. Andrew Dykens, Caryn E. Peterson, Hunter K. Holt, et al.
Frontiers in Public Health (2023) Vol. 11
Open Access | Times Cited: 44
Durability of single-dose HPV vaccination in young Kenyan women: randomized controlled trial 3-year results
Ruanne V. Barnabas, Elizabeth R. Brown, Maricianah Onono, et al.
Nature Medicine (2023) Vol. 29, Iss. 12, pp. 3224-3232
Open Access | Times Cited: 35
Current status and future directions for the development of human papillomavirus vaccines
Rui Wang, Hongpeng Huang, Chulin Yu, et al.
Frontiers in Immunology (2024) Vol. 15
Open Access | Times Cited: 9
Efficacy and immunogenicity of a single dose of human papillomavirus vaccine compared to multidose vaccination regimens or no vaccination: An updated systematic review of evidence from clinical trials
Hilary Whitworth, Sandra Mounier‐Jack, E Choi, et al.
Vaccine X (2024) Vol. 19, pp. 100486-100486
Open Access | Times Cited: 5
Pathways and processes to adopting or switching to a single-dose HPV vaccination schedule in low- and middle-income countries: a qualitative study
S. Roy, Megan Wysong, Erica N. Rosser, et al.
PLOS Global Public Health (2025) Vol. 5, Iss. 2, pp. e0004245-e0004245
Open Access
Cost-Effectiveness of Human Papillomavirus Vaccination in the UK: Two Versus Single-Dose of Nonavalent HPV Vaccination
Youngji Song, Wongyeong Choi, Eunha Shim
American Journal of Preventive Medicine (2024) Vol. 67, Iss. 2, pp. 231-240
Open Access | Times Cited: 4
Evaluation of a single-dose HPV vaccine strategy for promoting vaccine, health, and gender equity
Mathew Mercuri, Kristy Hackett, Ruanne V. Barnabas, et al.
The Lancet Infectious Diseases (2024) Vol. 24, Iss. 10, pp. e654-e658
Closed Access | Times Cited: 3
Improving HPV Vaccination Uptake Among Adolescents in Low Resource Settings: Sociocultural and Socioeconomic Barriers and Facilitators
Mia Ann Xu, Jasmin Choi, Ariadna Capasso, et al.
Adolescent Health Medicine and Therapeutics (2024) Vol. Volume 15, pp. 73-82
Open Access | Times Cited: 3
THE ROLE OF TRANSFORMING GROWTH FACTOR Β IN CERVICAL CARCINOGENESIS
Kleber Paiva Trugilo, Guilherme Cesar Martelossi Cebinelli, Eliza Pizarro Castilha, et al.
Cytokine & Growth Factor Reviews (2024)
Closed Access | Times Cited: 3
Rationale and design of a double-blind randomized non-inferiority clinical trial to evaluate one or two doses of vaccine against human papillomavirus including an epidemiologic survey to estimate vaccine efficacy: The Costa Rica ESCUDDO trial
Carolina Porras, Joshua N. Sampson, Rolando Herrero, et al.
Vaccine (2021) Vol. 40, Iss. 1, pp. 76-88
Open Access | Times Cited: 26
Optimal allocation strategies for HPV vaccination introduction and expansion in China accommodated to different supply and dose schedule scenarios: a modelling study
Tingting You, Xuelian Zhao, Shangying Hu, et al.
EClinicalMedicine (2022) Vol. 56, pp. 101789-101789
Open Access | Times Cited: 12
Contemplating the Human Papillomavirus (HPV) Vaccine Introduction in Pakistan: Is Now the Time?
Rabab Batool
American Journal of Tropical Medicine and Hygiene (2024) Vol. 110, Iss. 4, pp. 631-632
Closed Access | Times Cited: 1
Informing HPV vaccine pricing for government-funded vaccination in mainland China: a modelling study
Tingting You, Xuelian Zhao, Chenghao Pan, et al.
The Lancet Regional Health - Western Pacific (2024) Vol. 52, pp. 101209-101209
Open Access | Times Cited: 1
Single-dose human papillomavirus vaccination: an update
Aimée R. Kreimer, Deborah Watson‐Jones, Jane J. Kim, et al.
JNCI Monographs (2024) Vol. 2024, Iss. 67, pp. 313-316
Closed Access | Times Cited: 1
Human papilloma virus vaccination in the resource-limited settings of sub-Saharan Africa: Challenges and recommendations
Grant Murewanhema, Enos Moyo, Mathias Dzobo, et al.
Vaccine X (2024) Vol. 20, pp. 100549-100549
Open Access | Times Cited: 1
Informing Public Health Policies with Models for Disease Burden, Impact Evaluation, and Economic Evaluation
Mark Jit, Alex R. Cook
Annual Review of Public Health (2023) Vol. 45, Iss. 1, pp. 133-150
Closed Access | Times Cited: 3
Modeling the Health Impact and Cost-Effectiveness of a Combined Schoolgirl HPV Vaccination and Cervical Cancer Screening Program in Guangdong Province, China
Yating Huang, Dantao Zhang, Lihua Yin, et al.
Children (2024) Vol. 11, Iss. 1, pp. 103-103
Open Access
Potential impact of switching from a two- to one-dose gender-neutral routine HPV vaccination program in Canada: A mathematical modeling analysis
Mélanie Drolet, Jean‐François Laprise, Éléonore Chamberland, et al.
medRxiv (Cold Spring Harbor Laboratory) (2024)
Open Access
Switching from a 2-dose to a 1-dose program of gender-neutral routine vaccination against human papillomavirus in Canada: a mathematical modelling analysis
Mélanie Drolet, Jean‐François Laprise, Éléonore Chamberland, et al.
Canadian Medical Association Journal (2024) Vol. 196, Iss. 33, pp. E1136-E1143
Open Access
The Potential Impact of a Single Dose HPV Vaccination Schedule on Cervical Cancer Outcomes in Kenya: A Mathematical Modelling and Health Economic Analysis
Grace Umutesi, Christine Hathaway, Jesse Heitner, et al.
Vaccines (2024) Vol. 12, Iss. 11, pp. 1248-1248
Open Access
HPV16/18 antibodies 16-years after single dose of bivalent HPV vaccination: Costa Rica HPV vaccine trial
Carolina Porras, Byron Romero, Troy J. Kemp, et al.
JNCI Monographs (2024) Vol. 2024, Iss. 67, pp. 329-336
Open Access
Modeling the health and economic implications of adopting a 1-dose 9-valent human papillomavirus vaccination program in adolescents in low/middle-income countries: An analysis of Indonesia
Vincent Daniels, Kunal Saxena, Oscar Patterson‐Lomba, et al.
PLoS ONE (2024) Vol. 19, Iss. 11, pp. e0310591-e0310591
Open Access
Page 1 - Next Page

Scroll to top